Thomas Shrader
Stock Analyst at BTIG
(3.02)
# 1,172
Out of 5,090 analysts
67
Total ratings
45.76%
Success rate
1.11%
Average return
Main Sectors:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Reiterates: Buy | $32 | $19.96 | +60.32% | 3 | Dec 5, 2025 | |
| NRXP NRx Pharmaceuticals | Reiterates: Buy | $25 | $2.36 | +959.32% | 1 | Dec 3, 2025 | |
| BHVN Biohaven | Reiterates: Buy | $16 | $9.55 | +67.54% | 5 | Nov 18, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $27 | $13.43 | +101.04% | 1 | Nov 17, 2025 | |
| COYA Coya Therapeutics | Maintains: Buy | $15 → $16 | $6.02 | +165.78% | 3 | Nov 13, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $85 | $46.48 | +82.87% | 5 | Nov 10, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterates: Buy | $9 | $4.70 | +91.49% | 2 | Nov 10, 2025 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $39 | $30.87 | +26.34% | 2 | Nov 5, 2025 | |
| ACIU AC Immune | Reiterates: Buy | $8 | $2.80 | +185.71% | 3 | Nov 4, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $48 → $23 | $7.13 | +222.58% | 2 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.22 | - | 4 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $3.85 | +133.77% | 4 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $14 | $5.82 | +140.55% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $63 | $45.75 | +37.70% | 3 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $80.50 | -10.56% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.91 | - | 3 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.67 | +139.52% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.90 | - | 3 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $7.91 | +2,430.04% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $5.02 | +1,095.22% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $4.61 | +51.84% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.82 | +1,478.05% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $1.86 | +1,082.80% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.21 | +4,114.88% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $8.55 | +87.13% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.28 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.31 | +129.01% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $181.30 | +90.84% | 3 | Feb 21, 2019 |
Denali Therapeutics
Dec 5, 2025
Reiterates: Buy
Price Target: $32
Current: $19.96
Upside: +60.32%
NRx Pharmaceuticals
Dec 3, 2025
Reiterates: Buy
Price Target: $25
Current: $2.36
Upside: +959.32%
Biohaven
Nov 18, 2025
Reiterates: Buy
Price Target: $16
Current: $9.55
Upside: +67.54%
Alto Neuroscience
Nov 17, 2025
Initiates: Buy
Price Target: $27
Current: $13.43
Upside: +101.04%
Coya Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $15 → $16
Current: $6.02
Upside: +165.78%
Vaxcyte
Nov 10, 2025
Reiterates: Buy
Price Target: $85
Current: $46.48
Upside: +82.87%
Aldeyra Therapeutics
Nov 10, 2025
Reiterates: Buy
Price Target: $9
Current: $4.70
Upside: +91.49%
Stoke Therapeutics
Nov 5, 2025
Reiterates: Buy
Price Target: $39
Current: $30.87
Upside: +26.34%
AC Immune
Nov 4, 2025
Reiterates: Buy
Price Target: $8
Current: $2.80
Upside: +185.71%
Arcturus Therapeutics Holdings
Oct 22, 2025
Maintains: Buy
Price Target: $48 → $23
Current: $7.13
Upside: +222.58%
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.22
Upside: -
Oct 15, 2025
Reiterates: Buy
Price Target: $9
Current: $3.85
Upside: +133.77%
Oct 13, 2025
Maintains: Buy
Price Target: $7 → $14
Current: $5.82
Upside: +140.55%
Sep 29, 2025
Reiterates: Buy
Price Target: $63
Current: $45.75
Upside: +37.70%
Sep 8, 2025
Initiates: Buy
Price Target: $72
Current: $80.50
Upside: -10.56%
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.91
Upside: -
Mar 24, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $1.67
Upside: +139.52%
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.90
Upside: -
Oct 3, 2023
Initiates: Buy
Price Target: $200
Current: $7.91
Upside: +2,430.04%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $5.02
Upside: +1,095.22%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $4.61
Upside: +51.84%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.82
Upside: +1,478.05%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $1.86
Upside: +1,082.80%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.21
Upside: +4,114.88%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $8.55
Upside: +87.13%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.28
Upside: -
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.31
Upside: +129.01%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $181.30
Upside: +90.84%